Ulf Yrlid

12PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 12, 2026
Polarization of tumor-infiltrating macrophages predicts complete response to neoadjuvant treatment in patients with rectal cancer.

Aylin Alkan, Fabian Byvald, Rode Grönkvist

|Aug 25, 2023
Cholera intoxication of human enteroids reveals interplay between decoy and functional glycoconjugate ligands.

Akshi Singla, Andrew Boucher, Kerri-Lee Wallom

|May 14, 2023
A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma.

Azar Rezapour, Daniel Rydbeck, Fabian Byvald

|Jun 24, 2022
A Fraction of CD8+ T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells.

Frank Liang, Lisa M Nilsson, Fabian Byvald

|May 14, 2022
Impact of thymidine phosphorylase and CD163 expression on prognosis in stage II colorectal cancer.

Donia Kaidi, Louis Szeponik, Ulf Yrlid

|Oct 23, 2021
Antigen Presenting Cells from Tumor and Colon of Colorectal Cancer Patients Are Distinct in Activation and Functional Status, but Comparably Responsive to Activated T Cells.

Frank Liang, Azar Rezapour, Louis Szeponik

Pageof 2

Frequent Collaborators

3 joint publications

Louis Szeponik

3 joint publications

Eva Angenete

3 joint publications

Fabian Byvald

3 joint publications

Frank Liang